Skip to Main Content

++

INTRODUCTION

++

alclometasone (topical) (al-kloe-met-a-sone)

Aclovate

Classification

Therapeutic: anti-inflammatories (steroidal)

Pharmacologic: corticosteroids

++
Indications
++

Management of inflammation and pruritus associated with various allergic/immunologic skin problems.

++
Action
++

Suppresses normal immune response and inflammation. Therapeutic Effects: Suppression of dermatologic inflammation and immune processes. Adverse Reactions/Side Effects Derm: allergic contact dermatitis, atrophy, burning, dryness, edema, folliculitis, hypersensitivity reactions, hypertrichosis, hypopigmentation, irritation, maceration, miliaria, perioral dermatitis, secondary infection, striae. Misc: adrenal suppression (use of occlusive dressings, long-term therapy).

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess the area being treated to help document whether drug therapy is successful in resolving skin conditions.

  • Monitor any new or increased reactions at the site of application, including inflammation, irritation, infection, burning, swelling, exfoliation, and rash. Report severe or prolonged skin reactions to the physician.

  • Report signs of adrenal suppression, including hypotension, weight loss, weakness, nausea, vomiting, anorexia, lethargy, confusion, and restlessness.

++
Interventions
++

  • Protect skin from breakdown, especially over bony prominences.

++
Patient/Client-Related Instruction
++

  • Advise patients on long-term treatment to consult physician before stopping this medication. Stopping the medication suddenly may result in adrenocortical shock (severe hypotension, hypoglycemia, weakness, vomiting). If these signs appear, notify physician immediately; may be life threatening.

  • Check that the patient and family or caregivers understand topical application procedures, and adhere to the recommended dosing schedule.

++
Pharmacokinetics
++

Absorption: Minimal. Prolonged use on large surface areas or large amounts applied or use of occlusive dressings may increase systemic absorption.

++

Distribution: Remains primarily at site of action.

++

Metabolism and Excretion: Usually metabolized in skin.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (response depends on condition being treated)

ROUTE ONSET PEAK DURATION
topical min–hrs hrs–days hrs–days

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity or known intolerance to corticosteroids or components of vehicle (ointment base or preservatives); Untreated bacterial or viral infections.

++

Use Cautiously in: Hepatic dysfunction; Diabetes mellitus, cataracts, glaucoma, or tuberculosis (if significant systemic absorption occurs, condition may worsen); Patients with preexisting skin atrophy; OB/Lactation: Chronic use at high-dosages may result in adrenal suppression in mother and growth suppression in children; Pedi: Children may be more susceptible to adrenal and growth suppression).

++
Interactions
++

Drug-Drug: None significant.

++
Route/Dosage
++

Topical (Adults): Apply to affected area(s) 2–3 times daily (depends on condition being treated).

++
Availability
++

Cream: 0.05% Rx. Ointment: 0.05% Rx.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.